Joymed Tech Review: Major Global Medical Device Innovations in June 2024

Jul 11, 2024 14:51 CST Updated 14:51

TECLens

Refractive Surgery Technology Developer

Refractive Surgery

In June, Johnson & Johnson Vision proudly announced its role as the lead investor in TECLens, Inc.'s Series A funding round. TECLens, a pioneering medtech startup focused on transforming the field of refractive surgery, boasts a core breakthrough technology known as Quantitative Corneal Cross-Linking (qCXL™). This innovative approach redefines corneal reshaping with its incision-free, non-invasive nature, eliminating the need for laser ablation or complex surgical procedures.

The core technology that TECLens, Inc. relies on — Quantitative Corneal Cross-Linking (qCXL™) — is an innovative incision-free technique that has revolutionized traditional corneal reshaping methods. It enables precise adjustments to the cornea without relying on laser ablation or any invasive surgical procedures. This technology, with its unique advantages, has brought revolutionary changes to the field of ophthalmic medicine.

According to TECLens, the application scope of qCXL™ technology is extremely broad. It can not only effectively address complex ophthalmic diseases such as keratoconus but also provide effective intervention for vision problems in healthy eyes. For patients with presbyopia, this technology can significantly improve their near vision during reading, helping restore clear sight. For children, qCXL™ technology demonstrates great potential in controlling the progression of myopia, offering a new approach to prevent risks associated with high myopia. Additionally, the technology can accurately correct adult vision errors, including hyperopia and mild myopia, allowing patients to regain a clear visual experience.

Cardiovascular Surgery

In June, Terumo Cardiovascular, a global leader in cardiovascular surgical technology, announced that its next-generation CDI OneView monitoring system had received 510(k) clearance from the U.S. FDA. This achievement marks the system's application in extracorporeal circulation surgeries being recognized by authoritative institutions, and it is expected to significantly improve patient outcomes.

CDI OneView Monitoring System is a new-generation extracorporeal circulation surgical monitoring device developed by Terumo Cardiovascular Systems. The system aims to help doctors make more precise decisions during surgery by providing comprehensive patient parameter monitoring, thereby enhancing the safety of the surgery and the prognosis of the patient.

Comprehensive Monitoring of Key Parameters: The CDI OneView monitoring system can provide up to 22 critical patient parameters during extracorporeal circulation surgery, including but not limited to pH, PCO2, PO2, K+, temperature, SO2, HCT, and Hgb. Additionally, the system can calculate important indicators such as BE, HCO3, CI, O2ER, VO2, DO2, and AUC.

Ophthalmic Technology

In June, Carl Zeiss, the international leader in ophthalmic technology, announced a comprehensive functional upgrade to its flagship product—the new-generation high-throughput clinical OCT, Cirrus 6000. Highlights of the upgrade include a significantly expanded reference database, enabling doctors to make more precise disease diagnoses and evaluations. Additionally, high-speed imaging and visualization capabilities have been notably enhanced, bringing unprecedented clarity and efficiency to ophthalmic examinations. Furthermore, Carl Zeiss has reinforced the patient-centered design concept of the Cirrus 6000, streamlining workflows to ensure every patient receives more convenient and efficient ophthalmic diagnostic services. This series of upgrades will further enhance the accuracy and satisfaction of ophthalmic care.

Cardiovascular Ultrasound

On June 4, global medical technology giant Philips announced the launch of a new generation of artificial intelligence cardiovascular ultrasound platform, which has received U.S. FDA 510(k) approval, marking another significant breakthrough in the field of medical imaging technology. The platform integrates artificial intelligence applications into Philips' EPIQ CVx and Affiniti CVx ultrasound systems, significantly accelerating cardiac ultrasound analysis using advanced AI technology to provide doctors with more efficient and accurate diagnostic support. This innovation not only enhances the efficiency and precision of cardiac ultrasound examinations but also offers patients a better healthcare experience. As a leader in the medical technology sector, Philips continues to drive the intelligent development of medical imaging technology, contributing to the global healthcare industry.

Optometry Instrument

In June, Evolution Optiks Limited announced a significant milestone: its innovative light-field-driven subjective hyperopia refractor, the LFR-260, successfully obtained 510(k) approval from the U.S. FDA. This achievement not only marks the LFR-260's leading position in the field of ophthalmic technology but also reflects the FDA's recognition of its unique technical value.

Notably, LFR-260 had successfully obtained the European CE Mark certification in March 2024 before receiving FDA approval, further demonstrating the device's broad applicability and high standards of safety and efficacy in the international market. The approval of LFR-260 will undoubtedly bring revolutionary changes to ophthalmic examinations. Utilizing light-field technology, the device offers a faster and more accurate refraction experience, helping patients better understand their vision conditions and choose appropriate corrective solutions. At the same time, it provides ophthalmologists with a more powerful diagnostic tool, contributing to improved diagnosis and treatment of eye diseases.

Laparoscopic Surgery

On June 7, Asensus Surgical, a pioneer in the U.S. laparoscopic surgical robotics field, announced a definitive merger agreement with KARL STORZ, a long-established German medical device giant. This powerful collaboration marks a significant consolidation in the medical technology sector. Since its founding in 1945, KARL STORZ has been renowned worldwide for its development and production of endoscopes and high-end medical equipment, earning the title "King of Rigid Endoscopes," with an extremely high global market share. Asensus Surgical, as an innovator in laparoscopic surgical robots, will leverage this merger with KARL STORZ to drive deep integration in both medical robotics technology and the endoscopy field, collectively advancing surgical procedures toward greater precision and minimally invasive techniques.

Ankle and Knee Joint Replacement

On June 7, Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced that its orthopaedic subsidiary DePuy Synthes received 510(k) clearance from the U.S. FDA for the VELYS™ Robotic-Assisted Solution, expanding its application to unicompartmental knee arthroplasty (UKA). This milestone builds on the outstanding performance of the VELYS Robotic-Assisted Solution in total knee arthroplasty (TKA), with the platform already deployed across 20 markets, aiding over 55,000 surgeries and significantly improving surgical precision and patient recovery outcomes.

VELYS Robot Assists Surgeons in Better Protecting Soft Tissues, Evaluating Joint Stability, and Restoring Natural Knee Function by Providing Comprehensive Surgical Information. The Expansion of Indications Marks a Further Step for the VELYS Surgical Robot in the Orthopedic Field, Bringing Good News to More Patients in Need of UKA Surgery, While Also Demonstrating Johnson & Johnson's Continued Leadership in Medical Technology Innovation.

Anastomotic Leak

On June 15, SafeHeal, an innovator in the French medical device field, announced a significant achievement: its anastomotic leak solution, Colovac, has been awarded the "Breakthrough Device" designation by the U.S. FDA. This honor not only reflects the FDA's high recognition of Colovac's advanced technology and clinical potential but also marks SafeHeal's leading position in the field of medical device innovation.

Colovac, as a groundbreaking endoluminal bypass sheath, aims to address the complex and challenging medical issue of anastomotic leakage. Its unique design and innovative technology offer patients a new treatment option, with the potential to significantly improve treatment outcomes and accelerate the recovery process. The recent FDA Breakthrough Device Designation for Colovac will further promote its clinical application and market adoption, bringing benefits to more patients.

Pulse Ablation System

Boston, USA Successfully Hosted the Highly Anticipated Academic Conference in the Global Pacing and Electrophysiology Field – The Heart Rhythm Society Annual Meeting (HRS). As a benchmark for industry technology development, this annual meeting brought together numerous top scholars and experts to jointly discuss the latest advancements and future trends in the field.

During the conference, Richard Newitter, an analyst at Truist Securities, pointed out that the new pulsed field ablation (PFA) system became the focus of the meeting, receiving widespread attention and high praise from doctors. With its unique advantages, the system has caused a strong reaction in the U.S. market, and many institutions predict that PFA technology is expected to rise rapidly, becoming the mainstream ablation method for treating atrial fibrillation. This trend not only demonstrates the continuous innovation in medical technology but also brings new treatment hope for patients with atrial fibrillation.

A survey of some electrophysiologists in the United States also shows that, in the next 12 months, their use of PFA will increase from the current 9% to over 30%. Most doctors indicated that PFA would enable them to perform more cardiac surgeries.

Hair Loss

Recently, medical technology giant Lumenis announced a significant breakthrough: its self-developed innovative laser system for combating hair loss, FoLix, has successfully received formal approval from the U.S. FDA. This milestone achievement marks FoLix as the first and currently the only hair loss treatment device on the market certified by the FDA to use fractional laser technology, offering patients a safe, effective, and natural solution for hair loss.

The approval of the FoLix laser system is based on its outstanding performance and significant efficacy demonstrated in clinical trials. The system utilizes advanced fractional laser technology to precisely target the scalp, promoting follicle health and enhancing scalp blood circulation, effectively addressing hair loss and stimulating hair regrowth. The introduction of this innovative technology not only offers new treatment options for individuals experiencing hair loss but also further advances the fields of medical aesthetics and hair loss therapy.

Cardiac Surgery

In June, Medtronic launched its groundbreaking innovation in the field of cardiac surgery – the Avalus Ultra New Generation Surgical Aortic Tissue Valve.This product, built on a decade of clinical experience with the Avalus valve, is specifically designed to enhance surgical convenience and postoperative patient management.

The launch of Avalus Ultra, against the backdrop of the growing popularity of transcatheter aortic valve replacement (TAVR), reaffirms the irreplaceability and clinical value of surgical aortic valve replacement (SAVR). Its unique design simplifies the implantation process, not only reducing the operational burden on cardiac surgeons but also offering patients a more comfortable postoperative experience with fewer risks of complications. The introduction of Avalus Ultra undoubtedly represents a significant innovation in SAVR technology, injecting new vitality into the field of cardiac surgery.

Intervention Kit

In June, GE achieved a breakthrough in the medical technology field as its innovative product, the OmnifyXR Interventional Suite, made its debut in clinical surgery. This milestone marks a significant leap forward in medical imaging technology.

OmnifyXR Intervention Suite, the latest masterpiece from GE HealthCare, integrates advanced 3D visualization, augmented reality, and mixed reality technologies, providing doctors with an unprecedented surgical view and operational precision. During complex interventional procedures, doctors can use this suite to observe the patient's internal structures in real time, accurately locate lesions, significantly improving the success rate and safety of surgeries.

Aortic Guidewire

In June, medical technology giant Medtronic (NYSE: MDT) announced a significant product launch plan, set to introduce its innovative Streerant Aortic Guidewire in the U.S. and Canadian markets. Designed specifically to enhance catheter maneuverability during aortic procedures, this guidewire aims to simplify and optimize the processes of diagnosis and interventional treatments.

Streerant Aortic Guidewire: Another Powerful Tool in the Field of Aortic Surgery

Medtronic's newly launched Streerant Aortic Guidewire not only demonstrates the company's leading position in medical technology innovation but also further solidifies its competitive advantage in the aortic surgical instruments market. With the product's release, it is expected to bring safer and more efficient treatment options to patients with aortic diseases worldwide, driving the continuous advancement and development of medical technology.

Non-invasive Ultrasound

On June 20, 2024, Insightec (TECLens), a global leader in the development of non-invasive ultrasound technology devices, announced significant financing news, successfully raising $150 million (approximately 1.08 billion RMB).This funding will be specifically used to further advance the development and adoption of its revolutionary incision-free ultrasound neurosurgical technology, bringing unprecedented non-invasive treatment hope to patients with neurological disorders, gynecological conditions, and tumors worldwide.

The success of this financing round marks that Insightec's non-invasive ultrasound technology has gained high recognition and support from the international capital market. With the injection of funds, the company will continue to increase its R&D investment, accelerate the clinical validation and commercialization process of new technologies, and drive another major transformation in the global medical field.

Digital Ecosystem

On June 20, Johnson & Johnson Medical Technologies (NYSE: JNJ) took a significant step in the medical technology field by officially launching its carefully crafted open and secure digital ecosystem—Polyphonic.This innovative platform aims to create a more interconnected and efficient surgical environment for medical professionals worldwide, driving the healthcare industry towards deeper development in digital transformation.

The Core of the Polyphonic Ecosystem: Unparalleled Flexibility and Interoperability

Source: Siyu Medtech, China Biotechnology Network, The Paper, CCI Cardiovascular Physicians Innovation Club, Instrumentation Home, Bone Future, etc.

Click to follow "TECLens, Inc."

Stay Informed About the Latest Innovations in Global Medical Devices!

www.joymed-tech.com

Contact Us

TECLens (Shanghai) Co., Ltd.: 8th Floor, Building 10C, No. 2168 Chenxing Road, Minhang District, Shanghai

TECLens Medical Technology (Suzhou) Co., Ltd.: 3rd Floor, Building 1, No. 188, Jialing River Road, High-tech Zone, Suzhou City, Jiangsu Province, China

Changsha Juyi Medical Technology Co., Ltd.: 6th Floor, Building 1, Zhitingyuan West, No. 816 Zhenhua Road, Yuhua District, Changsha City, Hunan Province, China

Jiangsu Airis Medical Technology Co., Ltd.: No. 28, Xiahe Road, Wujin District, Changzhou City, Jiangsu Province

TECLens Singapore Company:55 Ayer Rajah Crescent #02-12 Singapore 139949

service@joymed-tech.com

Phone

021-34792237

Fax

021-34792239

Welcome to follow TECLens

If you like it, give it a thumbs up; if you love it, take a look; if you are passionate about it, share it.